Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document. (Q50784572)

19 March 2018

title

Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document. (English)

1 reference

19 March 2018

1 reference

Michael K Pugsley

1

1 reference

19 March 2018

Michael J Curtis

series ordinal

2

1 reference

19 March 2018

publication date

13 May 2006

1 reference

19 March 2018

Journal of Pharmacological and Toxicological Methods

published in

1 reference

19 March 2018

volume

54

1 reference

19 March 2018

issue

2

1 reference

19 March 2018

page(s)

94-98

1 reference

19 March 2018

Origins, practices and future of safety pharmacology

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Introduction to nonclinical safety pharmacology and the safety pharmacology society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

A one-step approach to the analysis of the QT interval in conscious telemetrized dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Can optical recordings of membrane potential be used to screen for drug-induced action potential prolongation in single cardiac myocytes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Effects of AF-DX116 and other muscarinic receptor antagonists on orthostatic hypotension in autonomic imbalanced (SART-stressed) rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Optimizing the experimental environment for dog telemetry studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

A model for evaluation of postural hypotension induced by drugs in conscious restrained normotensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Age-dependent effects on cisapride-induced QTc prolongation in the isolated guinea pig heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

A model of orthostatic hypotension in the conscious monkey using lower body negative pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Orthostatic hypotension in aging humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

A method for evaluating postural hypotension in conscious rabbits as a model to predict effects of drugs in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.05.002

10.1016/J.VASCN.2006.05.002

7 January 2021

Identifiers

DOI

1 reference

19 March 2018

release_bbs3iktn2rbwhlhanf6c2m62bm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bbs3iktn2rbwhlhanf6c2m62bm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 March 2018